We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+11.08%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$134B
AUM Growth
+$14.8B
Cap. Flow
+$2.42B
Cap. Flow %
1.81%
Top 10 Hldgs %
25.29%
Holding
4,017
New
232
Increased
1,652
Reduced
1,816
Closed
191

Sector Composition

Rank Sector Weight
1 Technology 15.71%
2 Financials 9.02%
3 Healthcare 7.82%
4 Industrials 6.8%
5 Consumer Discretionary 5.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FINV
3651
FinVolution Group
FINV
$1.05B
$85.1K ﹤0.01%
17,376
-2,842
-14% -$13.5K
MSC
3652
Studio City International Holdings
MSC
$325M
$84.1K ﹤0.01%
12,986
ORLA
3653
DELISTED
Orla Mining
ORLA
$84K ﹤0.01%
25,857
-9,101
-26% -$28.6K
WIA
3654
Western Asset Inflation-Linked Income Fund
WIA
$186M
$82.7K ﹤0.01%
+10,184
New +$80.5K
EVGO icon
3655
EVgo
EVGO
$497M
$81.5K ﹤0.01%
22,756
-6,100
-21% -$18.1K
EOD
3656
Allspring Global Dividend Opportunity Fund
EOD
$287M
$80.3K ﹤0.01%
18,492
-2,500
-12% -$10.3K
HTZWW
3657
Hertz Global Holdings Warrants
HTZWW
$103M
$79.8K ﹤0.01%
+14,568
New +$73.7K
ETWO
3658
DELISTED
E2open Parent Holdings
ETWO
$79.7K ﹤0.01%
18,152
-500
-3% -$1.77K
GERN icon
3659
Geron
GERN
$1.05B
$79.3K ﹤0.01%
37,600
-10
-0% -$19
LWLG icon
3660
Lightwave Logic
LWLG
$1.24B
$79K ﹤0.01%
15,859
-10
-0.1% -$47
FUSN
3661
CALL
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$78.8K ﹤0.01%
+31,500
New +$153K
SLRN
3662
DELISTED
ACELYRIN
SLRN
$78.5K ﹤0.01%
10,522
-8,034
-43% -$68.6K
GANX icon
3663
Gain Therapeutics
GANX
$89.1M
$77.7K ﹤0.01%
23,788
-10,012
-30% -$27.8K
AQN icon
3664
PUT
Algonquin Power & Utilities
AQN
$4.48B
$77K ﹤0.01%
+15,400
New +$90K
DMF
3665
DELISTED
BNY Mellon Municipal Income
DMF
$73.9K ﹤0.01%
11,376
-2,968
-21% -$17.7K
SLI
3666
Standard Lithium
SLI
$591M
$73.8K ﹤0.01%
36,538
-8,100
-18% -$20.2K
CRON
3667
Cronos Group
CRON
$1.14B
$72.5K ﹤0.01%
34,675
-4,607
-12% -$8.95K
DNMR
3668
DELISTED
Danimer Scientific, Inc.
DNMR
$72K ﹤0.01%
1,766
-156
-8% -$8.48K
ABCL icon
3669
AbCellera Biologics
ABCL
$3.06B
$70.7K ﹤0.01%
12,386
-3,746
-23% -$17.4K
PGY icon
3670
Pagaya Technologies
PGY
$1.67B
$69K ﹤0.01%
4,167
-6,830
-62% -$111K
SIGA icon
3671
SIGA Technologies
SIGA
$205M
$67.9K ﹤0.01%
12,120
ACTG icon
3672
Acacia Research
ACTG
$452M
$67.8K ﹤0.01%
17,300
PSNY icon
3673
Polestar Automotive Holding UK
PSNY
$1.97B
$66.7K ﹤0.01%
984
+263
+36% +$18.3K
SJT
3674
San Juan Basin Royalty Trust
SJT
$129M
$65.9K ﹤0.01%
12,982
-3,100
-19% -$20.7K
CDMO
3675
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$65.9K ﹤0.01%
10,138
-944
-9% -$6.08K

Similar funds

Raymond James & Associates's Q4 2023 Portfolio in Review

As of Q4 2023, Raymond James & Associates held 4,017 positions worth $134B, up 12% from $119B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Raymond James & Associates's Q4 2023 filing shows 232 new, 1,652 increased, 1,816 reduced and 191 closed positions. Its largest new stake was Delek US: 515,324 shares worth $13.3M. The largest sale was Pioneer Natural Resource Co., an estimated $124M.

By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q4 2023 buy was Delek US: 515,324 shares worth $13.3M.
  • Raymond James & Associates added most to State Street SPDR S&P 500 ETF Trust in Q4 2023, an estimated $219M increase.
  • Raymond James & Associates's biggest Q4 2023 reduction was Pioneer Natural Resource Co., cutting an estimated $124M.
  • Raymond James & Associates fully exited Kayne Anderson NextGen Energy & Infrastructure, Inc. in Q4 2023, selling an estimated $22.8M.
  • Raymond James & Associates's ten largest holdings make up 25% of its $134B portfolio in Q4 2023.
  • Raymond James & Associates opened 232 new positions and closed 191 in Q4 2023.
  • Raymond James & Associates's portfolio value rose 12% quarter-over-quarter to $134B.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.